Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
Salami, Falastin LU ; Spiliopoulos, Lampros LU ; Maziarz, Marlena LU
; Lundgren, Markus
LU
; Brundin, Charlotte
LU
; Bennet, Rasmus
LU
; Hillman, Magnus
LU
; Törn, Carina
LU
and Elding Larsson, Helena
LU
(2022)
In Journal of Immunology Research
2022.
- Abstract
- Objective. The objective of this study was to explore whether recombinant GAD65 conjugated hydroxide (GAD-alum) treatment affected peripheral blood T-cell subpopulations in healthy children with multiple beta cell autoantibodies. Method. The Diabetes Prevention–Immune Tolerance 2 (DiAPREV-IT 2) clinical trial enrolled 26 children between 4 and 13 years of age, positive for glutamic acid decarboxylase autoantibody (GADA) and at least one other autoantibody (insulin, insulinoma antigen-2, or zinc transporter 8 autoantibody (IAA, IA-2A, or ZnT8A)) at baseline. The children were randomized to two doses of subcutaneously administered GAD-alum treatment or placebo, 30 days apart. Complete blood count (CBC) and immunophenotyping of T-cell... (More)
- Objective. The objective of this study was to explore whether recombinant GAD65 conjugated hydroxide (GAD-alum) treatment affected peripheral blood T-cell subpopulations in healthy children with multiple beta cell autoantibodies. Method. The Diabetes Prevention–Immune Tolerance 2 (DiAPREV-IT 2) clinical trial enrolled 26 children between 4 and 13 years of age, positive for glutamic acid decarboxylase autoantibody (GADA) and at least one other autoantibody (insulin, insulinoma antigen-2, or zinc transporter 8 autoantibody (IAA, IA-2A, or ZnT8A)) at baseline. The children were randomized to two doses of subcutaneously administered GAD-alum treatment or placebo, 30 days apart. Complete blood count (CBC) and immunophenotyping of T-cell subpopulations by flow cytometry were performed regularly during the 24 months of follow-up posttreatment. Cross-sectional analyses were performed comparing lymphocyte and T-cell subpopulations between GAD-alum and placebo-treated subjects. Results. GAD-alum-treated children had lower levels of lymphocytes (109 cells/L) (), T-cells (103 cells/μL) (), T-helper cells (103 cells/μL) (), and cytotoxic T-cells (103 cells/μL) () compared to the placebo-treated children 18 months from first GAD-alum injection. This difference remained 24 months after the first treatment for lymphocytes (), T-cells (), T-helper cells (), and cytotoxic T-cells (). Conclusion. Our findings suggest that levels of total T-cells and T-cell subpopulations declined 18 and 24 months after GAD-alum treatment in healthy children with multiple beta-cell autoantibodies including GADA. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/948740ca-9541-41b6-9312-de25b1b992a0
- author
- Salami, Falastin
LU
; Spiliopoulos, Lampros
LU
; Maziarz, Marlena
LU
; Lundgren, Markus
LU
; Brundin, Charlotte
LU
; Bennet, Rasmus
LU
; Hillman, Magnus
LU
; Törn, Carina
LU
and Elding Larsson, Helena
LU
- organization
- publishing date
- 2022-05-25
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Immunology Research
- volume
- 2022
- article number
- 3532685
- publisher
- Hindawi Limited
- external identifiers
-
- scopus:85131344408
- pmid:35664355
- ISSN
- 2314-7156
- DOI
- 10.1155/2022/3532685
- language
- English
- LU publication?
- yes
- id
- 948740ca-9541-41b6-9312-de25b1b992a0
- date added to LUP
- 2022-08-04 14:58:53
- date last changed
- 2025-04-04 14:49:34
@article{948740ca-9541-41b6-9312-de25b1b992a0,
abstract = {{Objective. The objective of this study was to explore whether recombinant GAD65 conjugated hydroxide (GAD-alum) treatment affected peripheral blood T-cell subpopulations in healthy children with multiple beta cell autoantibodies. Method. The Diabetes Prevention–Immune Tolerance 2 (DiAPREV-IT 2) clinical trial enrolled 26 children between 4 and 13 years of age, positive for glutamic acid decarboxylase autoantibody (GADA) and at least one other autoantibody (insulin, insulinoma antigen-2, or zinc transporter 8 autoantibody (IAA, IA-2A, or ZnT8A)) at baseline. The children were randomized to two doses of subcutaneously administered GAD-alum treatment or placebo, 30 days apart. Complete blood count (CBC) and immunophenotyping of T-cell subpopulations by flow cytometry were performed regularly during the 24 months of follow-up posttreatment. Cross-sectional analyses were performed comparing lymphocyte and T-cell subpopulations between GAD-alum and placebo-treated subjects. Results. GAD-alum-treated children had lower levels of lymphocytes (109 cells/L) (), T-cells (103 cells/μL) (), T-helper cells (103 cells/μL) (), and cytotoxic T-cells (103 cells/μL) () compared to the placebo-treated children 18 months from first GAD-alum injection. This difference remained 24 months after the first treatment for lymphocytes (), T-cells (), T-helper cells (), and cytotoxic T-cells (). Conclusion. Our findings suggest that levels of total T-cells and T-cell subpopulations declined 18 and 24 months after GAD-alum treatment in healthy children with multiple beta-cell autoantibodies including GADA.}},
author = {{Salami, Falastin and Spiliopoulos, Lampros and Maziarz, Marlena and Lundgren, Markus and Brundin, Charlotte and Bennet, Rasmus and Hillman, Magnus and Törn, Carina and Elding Larsson, Helena}},
issn = {{2314-7156}},
language = {{eng}},
month = {{05}},
publisher = {{Hindawi Limited}},
series = {{Journal of Immunology Research}},
title = {{Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies}},
url = {{http://dx.doi.org/10.1155/2022/3532685}},
doi = {{10.1155/2022/3532685}},
volume = {{2022}},
year = {{2022}},
}